|
WO2021078889A1
|
|
Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763)
|
|
WO2021013772A1
|
|
Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
|
|
WO2021013771A1
|
|
Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt)
|
|
TW202102478A
|
|
Novel iron chelators
|
|
WO2020127928A1
|
|
Ferric carboxymaltose in the treatment of heart failure and in the treatment of congestion in heart failure
|
|
JOP20180036A1
|
|
Novel ferroportin-inhibitor salts
|
|
CO2018004165A2
|
|
Ferroportin inhibitors
|
|
AU2016205002A1
|
|
Methods and compositions for administration of iron
|
|
WO2015078900A1
|
|
Pharmaceutical composition, comprising phosphate binder particles
|
|
EP2978427A1
|
|
Fe(iii) complex compounds for treating and prophylaxis for anaemia symptoms and anaemia
|
|
AU2013366649A1
|
|
Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemia
|
|
AU2013206429A1
|
|
Methods and compositions for administration of iron
|
|
AU2013203333A1
|
|
Pharmaceutical compositions
|
|
EP2714030A1
|
|
Fe(iii) 2,4-dioxo-1-carbonyl complexes for use in the treatment and the prophylaxis of iron deficiency symptoms and iron deficiency anaemias
|
|
TW201302191A
|
|
Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
|
|
BR112013020916A2
|
|
compounds of general formula, composition and combined preparation
|
|
WO2012104204A1
|
|
Iron-carbohydrate complex compounds for the intravenous therapy of malaria
|
|
AU2011236068A1
|
|
Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
|
|
TW201136583A
|
|
Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
|
|
TW201111379A
|
|
Novel thiazole-and oxazole-hepcidine-antagonists
|
